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Glucuronidation and sulfation are phase 2 metabolic reactions catalyzed by large families of
different isoenzymes in man. The textbook view that glucuronidation and sulfation lead to the
production of harmless conjugates for simple excretion is not valid. Biologically active and toxic
sulfates and glucuronides are produced and lead to adverse drug reactions, including immune
hypersensitivity. Considerable variation in xenobiotic conjugation is observed as a result of altered
expression of UDP-glucuronosyltransferases (UGTs) and sulfotransferases (STs). Recent cloning
and expression of human cDNA encoding UGTs and STs has facilitated characterization of
isoform substrate specificity, which has been further validated using specific antibodies and
human tissue fractions. The availability of cloned/expressed human enzymes and specific
antibodies has enabled the investigation of xenobiotic induction and metabolic disruption leading
to adverse responses. Genetic polymorphisms of glucuronidation and sulfation are known to exist
although the characterization and assessment of the importance of these variations are
hampered by appropriate ethical studies in man with suitable safe model compounds. Genetic
analysis has allowed molecular identification of defects in well-known hyperbilirubinemias.
However, full characterization of the specific functional roles of human UGTs and STs requires
rigorous kinetic and molecular analyses of the role of each enzyme in vivo through the use of
specific antibodies and inhibitors. This will lead to the better prediction of variation of xenobiotic
glucuronidation and sulfation in man. Environ Health Perspect 105(Suppl 4):739-747 (1997)
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Introduction
Glucuronidation and sulfation ofpharmaco-
logically active xenobiotic compounds and
endogenous substances is a major phase 2
detoxication system in man and has pro-
found effects on thedisposition, metabolism,
and excretion ofmanydrugs (1,2).
Glucuronidation is a major detoxication
pathway in all vertebrates. Glucuronide
formation is catalyzed by a family ofUDP-
glucuronosyltransferases (UGTs) using
thousands of endobiotic and xenobiotic
compounds as substrates (3). The xenobi-
otic substrate range of an individual UGT
isoform may be dictated by the evolved
structure of an individual UGT to accept
endobiotic substrates such as bilirubin or a
steroid (4). A thorough understanding of
the evolved endobiotic UGT substrate
range is essential. Although an extensive list
ofdrugs is glucuronidated by humans (3),
it remains difficult to determine and pre-
dict UGT specificity. However, the fallibil-
ity ofthe evolved detoxication systems has
been revealed by the implication of drug
glucuronides in adverse drug reactions that
resulted in hypersensitivity of immune
response (5).
The cytosolic sulfotransferases (STs),
derived from the ST gene superfamily,
catalyze the sulfation ofa host ofxenobiotics
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and endogenous compounds, including
steroids, bile acids, thyroid hormones, and
neurotransmitters (2). Sulfotransferases of
various kinds may be found in species as
diverse as bacteria and man. Although in
mammals sulfation, in common with most
phase 2 reactions, is generally considered to
serve a detoxication function, it also plays a
role in, for example, steroid biosynthesis
(6). For certain compounds (e.g. aromatic
hydroxylamines and hydroxamic acids, ben-
zylic alcohols ofpolycyclic aromatic hydro-
carbons) sulfation is the terminal step in
their bioactivation to mutagens (7). Many
xenobiotics are substrates for both UGTs
and STs, and the different subcellular loca-
tion and kinetic properties of the enzymes
and the availability ofcosubstrate influence
the relative contribution ofeach system.
The availability ofcloned human UGTs
and STs has allowed for significant progress
(3), although our excitement needs to be
tempered by our lack ofknowledge ofthe
contribution ofeach isoform to xenobiotic
conjugation in vivo. Moreover, the use of
"rate" data obtained using recombinant cell
lines may lead to prediction of in vivo
pharmacokinetics, although there are a
number of limitations that have to be
circumvented (8).
This minireview will assess recent work
on the interindividual variation of glu-
curonidation and sulfation in man caused
by genetic differences in expression of
UGTs or STs. Further, we shall briefly
examine the bioactivation ofxenobiotics
following conjugation with sulfate and glu-
curonic acid as a mechanism of potential
toxicity in man.
The UGT Family of Genes
and Enzymes
More than 14 human liver UGT cDNAs
have been cloned and classified into two
subfamilies based on sequence analysis. The
UGT1 subfamily ofenzymes glucuronidate
xenobiotic phenols and bilirubin, while
UGT2 enzymes glucuronidate steroids and
bile acids. An early observation was that
UGT1 cDNA clones shared an identical
C-terminal coding sequence whereas
the N-terminal 246 amino acids show a
striking lack ofidentity (24 vs 49%) (9).
Southern blot analysis indicated that the
region encoding the conserved 3' half of
four separate human UGT1 cDNAs (the
common domain) was a single copy in the
human genome, suggesting a role for alter-
native splicing in the synthesis ofdifferent
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isoforms. In support of this, the common
domain and the isoform-specific 5' halfof
the four UGT1 cDNAs colocalized to chro-
mosome 2 at 2q.37 (10). Owens et al. (11)
described the existence ofa gene complex
by the isolation of overlapping cosmid
clones containing six alternative substrate-
determining first exons upstream of the
four exons that make up the common
domain. The human liver cDNA clone
HP4 isolated byWooster et al. (12) had the
same common domain sequence as other
UGT1 cDNAs but contained a novel sub-
strate-determining exon that was termed
UGT1*02 and was not among those
already genomically cloned. This suggested
that the UGTI gene locus was larger than
had previously been described, presumably
extending further upstream. Human
genomic Southern blotting indicated the
presence ofmultiple sequences homologous
to the 5' portion of UGTI*02 (13).
Further work has shown that the human
UGTI gene is a single-copy gene that con-
sists of4 common exons and more than 13
variable exons that span more than 200 kb
of the human genome (C Brierley and B
Burchell, unpublished data).
In contrast, comparison of members
of the UGT2 gene family, the steroid
metabolizing isoforms, indicates that
amino acid differences between different
isoforms of this family occur throughout
the length of the protein. Three UGT2B
genes were mapped to chromosome 4
using somatic cell hybrid cell lines and
polymerase chain reaction. To determine
whether they were clustered we screened
a yeast-affiliated chromosome (YAC)
library and isolated a five-YAC contig.
One ofthese YACs was found to contain
at least three UGT2B genes in 195 kb.
Fluorescence in situ hybridization analysis
indicated that the UGT2B gene cluster
was localized at 4ql3 (14).
Use ofCloned and Expressed
Human Liver UGTsto
Determine Substrate
Specificity
Human UGT isoforms have been identified
by gene sequencing and cDNAcloning (9),
but only a few of these are known to be
expressed in vivo. Indeed, one sequence is
known to contain stop codons that would
prevent functional enzyme expression (9).
Consequently, only a few human UGTs
have been substantially characterized.
Six cloned human hepatic UGT cDNAs
were stably expressed in tissue culture cell
lines. More than 100 drug xenobiotics and
endobiotics were used as substrates for glu-
curonidation catalyzed by the cloned
human transferases to determine the chem-
ical structure accepted as substrates (9).
Glucuronidation of drug molecules
containing a wide range of acceptor
groups has been reported including phe-
nols (e.g., propofol, paracetamol, nalox-
one), alcohols (e.g., chloramphenicol,
codeine, oxazepam), aliphatic amines (e.g.,
ciclopiroxalamine, lamotrigine, amitripty-
line), acidic carbon atoms (e.g., feprazone,
phenylbutazone, sulfinpyrazone), and car-
boxylic acids (e.g., naproxen, zomepirac,
ketoprofen). This indicates the variability
of acceptor groups that can be conjugated
to glucuronic acid in humans (3).
UGT1*6 exhibited a limited substrate
specificity for planar phenolic compounds,
whereas UGT 1*02 was more promiscuous
in acceptance of nonplanar phenols,
anthraquinones, flavones, aiphatic alcohols,
aromatic carboxylic acids, steroids, and
many drugs ofvaried structure.
A cloned human bilirubin UGT (UGT
1*1) accepted a wide diversity of com-
pounds such as phenols, anthraquinones,
flavones, and steroids. Seven substrates
were glucuronidated at rates comparable
to or higher than bilirubin. Octyl gallate
was glucuronidated at the highest rate
among all substrates tested. The UGT1*1
isoform exhibited stereospecificity towards
simple nonplanar phenols and estrogens.
The increasing number ofcarbon atoms in
the alkyl side chain of gallate analogues
improved the specific activity from no glu-
curonide formed with gallic acid to 0.72
and 1.90 mmol/min/mg protein in propyl
and octyl gallate, respectively (15).
Seventeen steroids were tested and only
four that had both 17p- and 3,-hydroxy
substituents were glucuronidated (15).
Recently, UGT1*4 has been shown to
catalyze the N-glucuronidation of drugs
and xenobiotics (9). Subfamily two con-
tains at least five UGTs catalyzing steroid or
bile acid glucuronidation UGT-2B4 and
UGT-2B7 (steroid/bile acid UGTs) also
catalyzed the glucuronidation of some
xenobiotics (9). Levels of UGT activity
were sufficient to allow determination of
kinetic parameters for the enzyme reaction.
Further, metabolism and toxicity ofdrugs
could be studied by their addition to
recombinant cell lines in culture, and
extraction ofthe media allowed analysis of
glucuronide formation. Suggested probe
substrates for individual UGT isoforms are
listed in Table 1.
Use ofAntibodies to Validate
Functional Specificity of
Human UGTs in Human Liver
Microsomes
Some problems in the use of expressed
human drug-metabolizing enzymes in the
analysis ofdrug metabolism and drug-drug
interactions have been discussed in a recent
commentary (8). The value of these in
vitro systems is their relevance to human
drug metabolism in vivo.
Recently, attempts have been made to
assess the contribution of a specific UGT
to the glucuronidation ofan endobiotic or
xenobiotic in a particular tissue by using
inhibitory antibodies. Monospecific poly-
clonal antibodies raised against the N-
terminal portion (14-150 residues) of
human liver UGT2B4 protein expressed
in E. coliwere used to immunoinhibit and
immunoprecipitate this transferase from
human liver and kidney microsomes (16).
These experiments demonstrated that
UGT2B4 activity was responsible for more
than 90% of the hyodeoxycholate 6-0-
glucuronidation activity in human liver
microsomes, but did not contribute signif-
icantly toward the glucuronidation of
estriol, 4-hydroxyesterone, 1-naphthol, or
hyodeoxycholic acid (16).
Similarly, antibodies were raised against
the N-terminal halfof UGT1*6 expressed
in E. coli, and immunoinhibition analysis
ofhuman liver microsomes demonstrated
that this isoenzyme represented between 20
and 50% ofthe total microsomal 1-naph-
thol glucuronidation (17). UGT activities
towards hyodeoxycholic acid, 4-hydroxy-
biphenyl, 4-t-butylphenol, and bilirubin
were not inhibited by these specific
anti-UGT1*6 antibodies.
Table 1. Probe substrates for human UDP-glucuronosyltransferases.
UGT-1 Subfamily(chromosome 2q37) UGT-2 Subfamily(chromosome 4ql3)
Isoenzyme Substrate Isoenzyme Substrate
UGT1*1 Bilirubin UGT2B4 Hyodeoxycholic acid
UGT1*4 Imipramine
UGT1*6 1-Naphthol UGT2B8 Androstanediol
UGT1*02 Propofol
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Biologically Active and
Potentially Toxic
Glucuronides
Glucuronidation has been described as a safe
detoxication process and glucuronides were
never considered biologically active interme-
diates. However, in recent years the poten-
tial toxicity and biological activity ofcertain
glucuronides have been well recognized.
There are several notable examples
reported in which such metabolites have
been found to be pharmacologically active.
(-)-Morphine is glucuronidated in a stereo-
selective manner to (-)-morphine-3-glu-
curonide and (-)-morphine-6-glucuronide
in the liver (18). Detailed pharmacologic
characterization of the glucuronides has
established that (-)-morphine-6-glucuronide
is 650 times more potent as an analgesic
than the parent drug, whereas morphine-3-
glucuronide is a potent antagonist of mor-
phine and has no analgesic activity (18).
This discovery has led to (-)-morphine-6-
glucuronide beingcommercially marketed.
The Role ofAcyl
Glucuronidation in Drug
Immune Hypersensitivity
Acyl glucuronides are formed when
conjugation with glucuronic acid occurs
via a carboxyl group, resulting in an ester-
type linkage. Ester-type glucuronides are
much more unstable than ether-linked glu-
curonides and can easily undergo nucle-
ophilic substitution. The chemical
properties of acyl-linked glucuronides are
extensively reviewed (19).
One important reaction that acyl glu-
curonides undergo is acyl migration, a
process whereby the aglycone moves from
the 1-hydroxyl group of the glucuronic
acid sugar to the 2-, 3-,or 4-hydroxyl
groups. This rearrangement of the glu-
curonide leads to ,B-glucuronidase-resistant
isomers and is completely reversible with
one exception: the Ci-glucuronide does
not appear to reform from the C2-isomer
(19). The extent of acyl migration may
only become detectable when the excretion
ofconjugates is impaired and their plasma
concentrations are raised (19).
The rate ofacyl migration differs from
compound to compound and their stability
is also highly variable (19). At physiologi-
cal or slightly alkaline pH, acyl migration
and hydrolysis of acyl glucuronides is
extensive (19).
A number of acyl glucuronides have
been shown to bind irreversibly to proteins
in vitro and in vivo (20). Evidence exists
for two principal mechanisms of this
reversible (covalent) binding; however, it is
not known which of these is principally
responsible (21).
Known Polymorphisms of
Glucuronidation in Man
Polymorphic drug glucuronidation in man
has not been extensively studied due to
problems in the selection ofsuitable drugs
for screening. The identification and mea-
surement of metabolites, including the
interaction between pathways of glu-
curonidation and sulfation, complicate
interpretation of the data. The known
polymorphisms are listed in Table 2.
Codeine glucuronidation was decreased
in Han Chinese when compared to a
Swedish population (22). Paracetamol
glucuronidation in small Chinese and
Caucasian groups has been compared but
no interethnic differences were observed
(23). In a more recent study ofparacetamol
glucuronidation, the distribution in a ran-
dom population appeared to be unimodel
although skewed (24). Glucuronidation
was also clearly affected by gender, oral
contraceptives, steroids, and smoking,
further indicating the problems in determi-
nation ofgenetic polymorphism (24).
Liu et al. (25) reported that the glu-
curonide excretion of the hypolipidemic
drug clofibrate in a healthy Caucasian
population followed a normal distribution,
whereas that offenofibrate appeared to be
distributed into the distinct normal
groups. However, a follow-up familial
study has shown lack of a genetic poly-
morphism in the glucuronidation of
fenofibrate (26).
Another study, ofa French population,
examined variation of dextrorphan glu-
curonidation. Again, a normal distribution
was observed (27). Analysis ofthe polymor-
phic variation ofdiflunisal phenol and acyl
glucuronide showed a unimodal population
distribution, especially when females using
oral contraceptives were excluded (28).
Recently, oxazepam administered as a
racemic mixture was shown to be preferen-
tially excreted as the (S)-glucuronide and a
low SIRglucuronide ratio was used to assess
poor glucuronidation of oxazepam (29). A
group of 10% ofthe whole population was
determined to be poor glucuronidators of
(S)-oxazepam which suggested a genetic
relationship to the UGT2B7 isoform.
However, oxazepam may not be solely glu-
curonidated by UGT2B7 in vivo and this
relationship requires additional investiga-
tion. Nonetheless, this is the most interest-
ing example of a polymorphism of drug
glucuronidation to date.
Menthol glucuronidation is consider-
ably reduced in many patients with Crigler-
Najjar syndrome, such that the menthol
excretion test is often used as a confirma-
tory diagnosis ofthe disorder and as a study
of the genetic inheritance of the disease
(30,31). In a study of a family in which
two CN children were born from the same
marriage, only 5 of 16 members ofthe fam-
ily showed a normal menthol glucuronide
output. This menthol test demonstrated
likely heterozygotes in the family members
who were not revealed by serum bilirubin
analyses (30). In other studies the test failed
to discriminate between icteric patients and
anicteric family members suspected to be
heterozygotes. Indeed, jaundiced patients
may show normal menthol glucuronide
excretion (32). Bloomer et al. (33) also
detected normal menthol conjugation in
the parents ofa Crigler-Najjar child. These
accumulated data suggest that menthol glu-
curonidation is independently variable
within the population.
Menthol is conjugated with glucuronic
acid prior to excretion in bile and urine
(31) and is therefore an interesting, rela-
tively harmless test compound for study
ofpolymorphism ofdrug glucuronidation
in man. However, glucuronidation of
menthol was only reduced to about 20%
of controls in some of the Crigler-Najjar
type 1 patients. This suggests that men-
thol may be a substrate for more than one
UGT isoenzyme, which may complicate
studies of menthol glucuronidation in the
normal population.
The known defects ofglucuronidation
in humans are best illustrated within the
group ofa hereditary hyperbilirubinemias,
(5) in which molecular genetic studies
have revealed the association between
genetic defects and loss offunction.
Table 2. Polymorphisms of human UGT genes.
Gene Defect Substrate/Activity Remarks
UGT1 Exons 1*1,2,3,4,5 Bilirubin reduced to 0-10% Crigler-Najjar syndrome (1,2)
UGT1 5'-noncoding promoter region Bilirubin reduced to 35% Gilbert's disease patients
UGT1 Unknown Menthol reduced to 20% Linked with Crigler-Najjar
UGT2B7 Unknown (S)-Oxazepam, valproate reduced
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Crigler-NajjarSyndrome
Crigler-Najjar syndrome (CN) is a familial
form ofsevere unconjugated hyperbiliru-
binemia caused by a dysfunction in biliru-
bin glucuronidation. The molecular basis of
these syndromes has recently been charac-
terized by enzymological, immunochemi-
cal, and molecular genetic analysis. In vitro
analysis of CN type 1 liver samples has
revealed that as well as showing complete
absence ofbilirubin UGT activity, some of
these patients also poorly glucuronidate
phenols, 5-hydroxytryptamine, and the
drugs ethinylestradiol and propofol (3).
Recently, as a result of the elucidation
ofthe UGTI gene complex, several groups
have determined some of genetic lesions
that cause CN (5). The mutations that
result in CN syndrome have been found in
the exons 1,2,3,4, and 5 encoding the con-
stant region ofall UGT1 proteins, which
explains the decreased activity towards
other aglycones as well as bilirubin (5).
More than 20 genetic lesions have been
demonstrated to be associated with the
severe hyperbilirubinemia ofCN (5).
GilbertsSyndrome
Gilbert's syndrome (GS), a familial
hyperbilirubinemia determined to be pre-
sent in up to 5% of the population in
1980, is characterized by a mild unconju-
gated hyperbilirubinemia (34). Decreased
formation of bilirubin diglucuronide and
increased levels of bilirubin monoglu-
curonide were found in bile in parallel with
decreased hepatic UGT activity (35). This
disease provides an opportunity to study
variation in drug glucuronidation due to
the prevalence of the familial disorder
within the population. There is no obvious
indication of impaired drug oxidation,
acetylation, or sulfation (36). Decreased
clearance ofseveral drugs, such as tolbu-
tamide, rifamycin, josamycin, and parac-
etamol, has been observed (37), although
decreased clearance was not apparently
associated with a decreased rate ofglu-
curonidation measured in overnight urine
samples (36).
De Morais et al. (38) have reported that
paracetamol glucuronide formation, mea-
sured in six GS patients by clearance from
plasma within 2 hr, was 31% lower than in
normal controls. The timing of measure-
ments may be critical in determination of
these significant differences.
Recent work has shown that the
mildly affected members of families in
which CN type 2 occurs are heterozygous
for mutations in the UGT subfamily 1
(UGTI genes) may be classified as GS (39).
However, the incidence of CN-2 in the
population is very rare and the frequency of
alleles causing CN-2 would not be sufficient
to explain the population incidence ofGS.
A study by Bosma et al. suggested a cor-
relation between homozygosity for a 2bp
insertion in the TATA box upstream of
UGTI*1 exon 1 and GS; no mutations
were found in the coding sequence ofthe
UGTI*1 gene (40). We demonstrated that
the primary genetic factor contributing to
the variation in the serum and total biliru-
bin concentration in an eastern Scottish
population is the sequence variation
reported by Bosma et al. (40); a direct cor-
relation is only revealed by a controlled
study ofa drug-free, alcohol-free nonsmok-
ing population (41). We showed that the
7/7 genotype is associated with GS and
occurs in 10 to 13% ofthe population (41).
Drugs, alcohol, and smoking induce
human bilirubin UGT (41) and thereby
interfere with the phenotype in the general
population, creating latent GS patients.
It is now recognized that there are bet-
ter xenobiotic substrates ofUGT1*1 (the
major bilirubin-metabolizing form) than
bilirubin itself, examples including octyl
gallate and emodin (15), which obviously
have the potential to cause jaundice by
competitive inhibition ofUGT1*1, espe-
cially in GS patients in whom hepatic
activity is reduced to 35% ofnormal levels.
Xenobiotic Induction and
Physiological Perturbation
in Humans
Induction ofglucuronidation reactions has
also been reported in humans. (3). Indoles
present in cruciferous vegetables (brussel
sprouts and cabbage) appear to modestly
enhance oxazepam and paracetamol glu-
curonidation (42). The anticonvulsant
agents phenobarbitone, phenytoin, and
carbamazepine either separately or in com-
bination induce the glucuronidation of
paracetamol (43) and possibly norcodeine
(24). Carbamazepine also induces valproic
acid glucuronidation (44). Coadmini-
stration ofphenobarbitone and phenytoin
induces chloramphenicol glucuronidation
(45). Several oral contraceptive drugs
increase the glucuronidation of parace-
tamol (24), clofibric acid (46), and
temazepam (47).
Cimetidine has been shown to
specifically increase the urinary excre-
tion of naproxen acyl glucuronide, in
contrast to other naproxen glucuronide
metabolites (48).
Dexamethasone and phenobarbital
cause up to a 2-fold induction ofdigitoxi-
genin monodigitoxoside UGT in human
liver (49). Ethanol treatment of a GS
patient led to a 3-fold decrease in serum
bilirubin associated with a corresponding
2.5-fold increase in hepatic bilirubin UGT
activity (50), and bilirubin UGT mRNA,
encoded by the UGTJ*1 gene, was
reported to be selectively induced in human
livers from patients treated with phenytoin
and phenobarbital (51). Indeed, wide-
spread consumption of therapeutic and
social drugs, e.g., ethanol, and exposure to
environmental chemicals induce UGTs and
may mask genetic variation, for example in
GS patients (above).
Thyroid Hyperplasia
Plasma thyroxine (T4) concentrations are
monitored by the pituitary gland; if thy-
roxine levels decrease, the pituitary secretes
thyroid-stimulating hormone (TSH) that
increases the production of thyroxine by
the thyroid follicular cells. TSH synthesis
is under negative feedback regulation by
thyroxine; hence, when plasma thyroxine
concentrations return to normal TSH
secretion stops. However, continuous
depression ofplasma thyroxine results in
sustained increases ofplasma TSH, leading
to follicular cell proliferation, hyperplasia,
and ultimately neoplasia (52). Plasma thy-
roxine levels may be decreased by either
direct inhibition of its synthesis or by
increased metabolism and excretion. A
major route of thyroxine metabolism is
conjugatiort with glucuronic acid in the
liver, followed bybiliary excretion.
Rats given four microsomal enzyme
inducers had elevated UGT activity toward
T3 and T4 ofup to 60%, and the circulat-
ing T3 and T4 concentrations fell to 70 to
75% of control levels. Furthermore this
reduction in hormone levels was not medi-
ated by the thyroid (53). This effect results
in continuous TSH synthesis and thyroid
hyperplasia. This hyperplastic mechanism is
one that is potentially operative in many
species induding humans. Glucuronidation
ofthyroxine is catalyzed by bilirubin UGT
and other transferases in human liver (54).
Therefore chemical induction ofbilirubin
UGT by alcohol and other drugs could
increase risk of hypothyroidism and
subsequent thyroid hyperplasia.
Xenobiotic Inhibition
ofGlucuronidation
In intact cell preparations (isolated cells,
perfusions, in vivo) glucuronidation may
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be inhibited by either a decrease of
UDPGA availability or by inhibition
decrease ofUGT activity. No highly effi-
cient, selective inhibitors ofglucuronida-
tion in vivo or in intact cells are available
at present, although Mulder et al. (55)
present a fairly recent review.
The studies of inhibition ofUGTs are
difficult and confused by the microsomal
membrane location oftransferases. Many
compounds that have been considered
inhibitors ofglucuronidation cause mem-
brane disruption or reduce cellular
UDPGA concentrations (56).
Specific analysis is perhaps more easily
achieved by measurement ofendogenous
compound glucuronidation such as the
inhibition of bilirubin UGT activity.
Gentamycin was shown to be a weak
inhibitor of bilirubin UGT in vitro, but
also inhibited salicylamide glucuronidation
in vivo (57). Bilirubin has been shown to
specifically inhibit 3a-hydroxyestradiol
glucuronide formation, but not 170-
hydroxyestradiol glucuronide formation by
human liver microsomes, indicating a
stereospecific role ofbilirubin UGT in for-
mation of this endogenous glucuronide
(15). Novobiocin, which caused unconju-
gated hyperbilirubinemia in animals and
man, was shown to exert noncompetitive
inhibition of rat microsomal UDP-glu-
curonosyltransferase in digitonin-activated
preparations with either bilirubin or UDP-
glucuronic acid. Human microsomal
bilirubin UGT activity was also inhibited
by novobiocin, whereas 1-naphthol UDP-
glucuronosyltransferase was unaffected
(58). Further studies with purified rat liver
bilirubin UGT suggested that novobiocin
competitively inhibited bilirubin binding
to the enzyme, but the drug did not appear
to be a substrate for the purified enzyme.
D-ring glucuronides ofestriol, testos-
terone, and dihydrotestosterone possess
pharmacological activity and mediate
cholestasis (59). In contrast, A-ring conju-
gates of these steroids are inactive (60).
Human bilirubin UGT is the major
enzyme responsible for 3-estradiol-3-glu-
curonide formation in human liver (15).
Therefore, the bile ductular cholestasis
described in CN patients might be due to
the genetic defect in the human bilirubin
UGT, which in turn results in excess for-
mation of the cholestatic E2-17f3-glu-
curonide rather than the noncholestatic
E2-3-glucuronide (61).
Androsterone glucuronide is the
predominant C-19 steroid glucuronide
in plasma (62). The marked rise in
testosterone during puberty was strongly
correlated with increases of androsterone
glucuronide and androstane-3a, 17,-diol
glucuronide. Both steroid glucuronides
are plasma biochemical markers ofadrenal
hyperandrogenism in hirsuitism in
women (63) and in virilizing congenital
adrenal hyperplasia (64). Direct inhibi-
tion of UGTs by competitive xenobiotics
could significantly affect the production
of steroid glucuronides and, in turn, the
physiological function responsive tissues
such as ovary.
Tertiary amine drugs, chlorpromazine,
amitriptyline, imipramine, promethazine,
and cyproheptadine were potent inhibitors
of the glucuronidation of testosterone,
androsterone, and estriol. Structural features
required for inhibition were a rigid tricyclic
ring and either a dimethylaminopropyl or a
methylpiperidine side chain (65).
Ketoprofen and other substrates of
human UGT2B7 are competitive inhibitors
of(S)-oxazepam glucuronidation in human
liver microsomes, but not effective
inhibitors of(R)-oxazepam glucuronidation,
indicating a stereoselective, competitive
inhibition ofoxazepam glucuronidation,
which may be catalyzed by two different
UGTs (66).
Organization and
Characterization ofthe
Human Sulfotransferase
Family
In man, five ST gene products have been
identified and characterized and, as is the
case for most mammalian STs, these can be
classified into two distinct subfamilies
(based on their amino acid sequence iden-
tities and substrate specificities): phenol ST
(PST) and hydroxysteroid ST (HST)
(Table 3) (67,68). PSTs, particularly M-
PST and P-PST, sulfate numerous xenobi-
otics, thyroid hormones, and biogenic
amines; the family also includes the estro-
gen ST (EST) that sulfates both endoge-
nous and xenobiotic estrogens. A (to date)
single but somewhat promiscuous human
HST isoform exists, which sulfates many
diverse steroids, bile salts, cholesterol, and
xenobiotic alcohols. It is likely, however,
that other human STs exist, since addi-
tional STs are present in other mammalian
species, for example, a member of the rat
PST family (STICI) that shows remark-
able specificity for aromatic hydroxy-
lamines and hydroxamic acids (69). A new
nomenclature system for the classification
ofall STs is currently being devised, which
will be generally in line with those adopted
for the cytochromes P450 and the UGTs.
cDNAs encoding all the known human
STs have been isolated, sequenced, and
expressed either in bacterial or mammalian
cell-based heterologous expression systems.
These are proving valuable in defining the
boundaries of substrate specificity of the
various forms. In general, the kinetic and
catalytic properties of these recombinant,
expressed STs are as expected. There
appears to be some microheterogeneity at
the amino acid sequence level with certain
STs, in particularwith the P-PST.
cDNAs encoding this isoform have
been isolated in a number oflaboratories,
and at least three allelic variants differing
by up to five amino acids seem to be pre-
sent within the population. The effects of
these variants on the substrate specificity
and kinetic parameters of P-PST remain
to be determined. A P-loop motif
(GXXGXXK) located towards the C-termi-
nus is conserved in all sulfotransferases,
and this has been demonstrated to be
involved in binding the cosubstrate,
3'-phosphoadenosine 5'-phosphosulfate
(PAPS) (70). Site-directed mutagenesis
experiments are beginning to identify
amino acids important for catalysis (71).
Each ST appears to be transcribed
from a single gene, although there is some
evidence for alternate splicing from 5'
noncoding "exons" that may play a role in
tissue-specific expression. STs are
expressed in many tissues, with marked
selectivity for the different forms. P-PST
appears almost ubiquitous and the liver is
a major site for P-PST, HST, and EST
expression, although M-PST is a minor
form in this tissue. This is in contrast to
the small intestine, where M-PST appears
to be the major form. HST plays a
Table 3. The human sulfotransferase family.
ST isoform Subfamily Chromosome Prototypical substrates References
P-PST(ST1A3) PST 16p 4-Nitrophenol, minoxidil Dooley et al. (92)
ST1A2 PST 16p 4-Nitrophenol, minoxidil Her et al. (95)
M-PST PST 16p Dopamine, 5-hydroxytryptamine Dooley et al. (92)
EST PST 4q P-estradiol, 17a-ethinylestradiol Heret al. (93)
HST HST 19q Dehydroepiandrosterone, pregnenolone Otterness et al. (94)
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fundamental biological role during devel-
opment, as it is responsible for the produc-
tion ofdehydroepiandrosterone sulfate by
the fetal adrenal gland during the second
half of pregnancy (72), which in turn is
the major substrate for placental estrogen
biosynthesis. Both M- and P-PST are
expressed in the brain, although the func-
tion remains unclear. Platelets, which
contain P-PST and M-PST but not EST
or HST proteins, are one of the most
widely studied tissues, although their rele-
vance to other tissues has remained a
matter ofsome debate.
The availability of good quality, iso-
form-specific antibodies is essential for the
thorough characterization and analysis of
any enzyme family, and this has proven
particularly difficult for the STs. Numerous
antibodies have been raised against, in par-
ticular, rat and human STs, but the high
degree of sequence identity among the
three known human PSTs (P-PST, ST1A2,
and M-PST) means that antibodies distin-
guishing between them have so far eluded
the field. It was demonstrated that synthetic
peptides could be used to induce antibodies
against human HST and members of the
PST family (73), and advancement ofthis
work has now yielded the first antibodies
specific for M-PST and for P-PST (Rubin
et al., unpublished data).
Biologically Active
and Toxic Sulfates
It has been known (but perhaps notwidely)
for many years that sulfation does not
always result in a reduction in biological
activity, from Millers' pioneering work on
the role ofsulfation in the bioactivation of
chemical procarcinogens (7). For the anti-
hypertensive and hypertrichotic drug
minoxidil, bioactivation by sulfation is
beneficial, since the sulfate ester is the
pharmacologically active species (74).
Elegant experiments demonstrated that the
ST responsible for this reaction is expressed
in the hair follicles, providing in situ activa-
tion oftopically applied minoxidil (75),
which has found clinical application in the
treatment ofbaldness.
A classical pathway ofbioactivation of
aromatic amines such as 2-aminofluorene
involves N-hydroxylation by cytochrome
P450 (forming an aromatic hyc!roxyl-
amine) followed by reaction with PST to
form a highly unstable N-0-sulfate that
rapidly and spontaneously decomposes,
resulting in the formation ofa highly reac-
tive arylnitrenium ion that is able to
adduct to DNA and proteins.
The requirement for sulfation in the
bioactivation of promutagens can be
demonstrated in vitro using the Ames test
(76). There is also a significant amount of
good (albeit circumstantial) evidence for
the key role ofsulfation in the bioactiva-
tion ofcertain chemical procarcinogens in
vivo. The brachymorphic mouse, which
has a dramatically reduced capacity for
PAPS synthesis, is remarkably resistant to
chemical-induced cancer when fed com-
pounds (such as aromatic amines) that
require sulfation for activation to mutagens
(7). Male rats are much more susceptible
to hepatocarcinogenesis following exposure
to aromatic amines than female rats, and
male rats have up to 10-fold higher levels
ofexpression of the PST(s), which sulfate
aromatic hydroxylamines; and the carcino-
genicity of aromatic amines is much
reduced when coadministered with potent
inhibitors of PSTs (7). Human liver
PST(s) are primarily responsible for the
sulfation ofaromatic hydroxylamines and
hydroxamic acids (77), whereas benzylic
alcohols ofpolycyclic aromatic hydrocar-
bons (which are also conditional on sulfa-
tion for bioactivation) are preferentially
sulfated by HST (78).
The upsurge of interest in sulfation
and the STs involved in these bioactiva-
tion pathways is principally a result oftwo
factors. First, the demonstration that the
hydroxylated metabolites of heterocyclic
amines formed during the cooking of
meat and fish, which are widely believed
to play an important role in colon cancer,
are substrates for PST(s) (79,80). Second,
there appears to be polymorphic expres-
sion of P-PST within the human popula-
tion. An individual's genetic complement
ofSTs may therefore be an important risk
factor in susceptibility to cancer of the
colon and possibly other tissues. Testing
this hypothesis is therefore an important
health priority.
Known Polymorphisms
of Sulfation in Man
Platelet P-PST and M-PST activity varies
widely within the population (81). Much
ofthe work on sulfation pharmacogenetics
has been done using the platelets because
they are a readily accessible tissue and
because the level of P-PST in platelets
appears to correlate with that in other tis-
sues from the same individual, in particular
the cerebral cortex, small intestinal mucosa
and liver (81). Platelets, of course, are
unlikely to play a role in drug metabolism;
the simple measurement ofenzyme activity
may not provide the whole picture, since
there are several closely related PSTs
known to exist in humans with undoubted
overlapping substrate specificity. The dis-
covery of isoenzyme-selective substrates is
therefore critical although potentially very
difficult when P-PST (ST1A3) and ST1A2
share 96% amino acid identity (67). The
difficulties attached to producing molecu-
lar probes to distinguish the various forms
at the DNA, mRNA, or protein level are
also considerable.
Classical enzyme activity measurements
in platelets from a large number ofindivid-
uals and within families have suggested a
significant heritability for both P- and
M-PST, and polymorphic expression ofthe
P-PST form in this tissue (81). The correla-
tion between P-PST enzyme activity and
enzyme protein levels in platelets has also
been shown (81). Similarly, statistically sig-
nificant correlations between the extent of
paracetamol (acetaminophen) sulfation in
vivo and the levels ofplatelet M-PST and
P-PST enzyme activity (paracetamol is a
substrate for both enzymes) have been
demonstrated (82), although this drug is
also subject to other metabolic routes.
There is also population variability in
the expression of human HST, with an
apparent bimodal distribution of enzyme
activity in a series of 94 liver samples,
although the variation was only 4.6-fold
(83). Recent sequence analysis of the gene
coding for HST indicated the presence of
restriction fragment length polymorphisms
and nucleotide mutations within the popu-
lation, and such analyses will facilitate the
study ofmolecular mechanisms ofST reg-
ulation in man (84).
Regulation of
Sulfotransferases
by Xenobiotics
Sulfotransferases are considered to be
refractory to induction by "classical" xeno-
biotic inducers. Recent analysis of the
effect of peroxisome proliferators on rat
liver ST expression demonstrated a sup-
pression ofthe major rat PSTs ASTIV (or
STIAl) and STlCl (85), and the suppres-
sion ofrat liver HST expression after treat-
ment with 3-methylcholanthrene has also
been shown (86).
Xenobiotic Inhibition of
Sulfation and Human Risk
InhibitioninIntactCells and in Vivo
Sulfation can be inhibited either by direct
inhibition ofthe enzymes or by interfering
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with the biosynthesis of the cosubstrate
PAPS through, for example, reduction in
inorganic sulfate availability. 2,6-Dichloro-
4-nitrophenol (DCNP) and pentachloro-
phenol (PCP) are potent inhibitors ofPST
activity (in humans, specifically of the
P-PST isoform[s]). Inhibition ofsulfation in
vivo, in perfused organs and intact cells, and
in vitrocan be achieved with these chemicals
andwith manyothercompounds (87).
nhibiton ofSTActivity in Vt"r by
Drugs andDietryCompounds
The important role ofsulfation in modu-
lating the biological activity ofkey endo-
biotics and the fact that all human STs
number both xenobiotics and endobiotics
among their substrates mean that inter-
ference with this function by inhibition
may have important consequences for the
body's physiology and biochemistry.
The compounds DCNP and PCP, par-
ticularly potent and selective inhibitors of
human P-PST in vitro, were used in the
pre-recombinant DNA technology era as
tools for classification of the different
human STs. Studies on the inhibition of
human liver steroid sulfation by a wide
range ofdrugs demonstrated that a number
of commonly used pharmaceuticals were
potent inhibitors ofthe sulfation ofDHEA
by HST and the sulfation of estrone by
EST (88). Clomiphene, danazol, spirono-
lactone, cyproterone, and chlorpromazine
were all able to inhibit HST activity with
an IC50 value ofless than 10 pM, and EST
activity was inhibited by cyclizine, ibupro-
fen, chlorpheniramine, dimenhydrinate,
and tamoxifen, again with IC50 values <10
pM. These observations have implications
for adverse drug reactions; but their effects
in vivo, either in humans or animals,
remains to be determined. Another obvi-
ous source ofxenobiotic inhibitors is the
diet, and a number ofnatural and synthetic
dietary chemicals were shown to potently
inhibit the sulfation of 17a-ethinylestra-
diol and dopamine (89). These included
vanillin (a naturally occurring flavoring),
octyl gallate (an antioxidant), and tar-
trazine (a synthetic colorant). A number of
flavonoids, such as quercetin, are also
potent inhibitors of ST activity (90); and
red wine, which contains very high levels
of polyphenolic compounds, is a very
potent and selective inhibitor ofhuman
P-PST with a 2000-fold dilution resulting
in 50% inhibition ofthis enzyme activity
(91). The importance of these dietary
inhibitors may lie in their ability to inhibit
the bioactivation ofdietary procarcinogens
by STs (particularly P-PST) and thus act as
naturalchemoprotectants.
Concluding Remarks
The "undergraduate textbook" concept of
glucuronidation and sulfation as purely
detoxication mechanisms is clearly out-
dated. As we understand more about these
complex and fascinating enzyme systems, it
becomes increasingly clear that there is a
fine balance between their beneficial and
harmful properties. The combination ofan
individual's genetically determined comple-
ment ofthese, and other, xenobiotic metab-
olizing enzymes and the environmental
pressures upon them are obviously major
factors in determining which way the bal-
ance tips. Not until we have learned much
more of the structure/function relation-
ships, regulation and pharmacogenetics of
the UGTs and STs, however, will we be
able to fully exploit their potential as risk
assessment tools.
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